X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6649) 6649
Book Review (981) 981
Publication (346) 346
Newspaper Article (55) 55
Book / eBook (52) 52
Newsletter (23) 23
Magazine Article (15) 15
Book Chapter (14) 14
Conference Proceeding (6) 6
Dissertation (4) 4
Reference (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (6237) 6237
humans (5571) 5571
female (3544) 3544
antibiotics, antineoplastic - adverse effects (3217) 3217
male (3051) 3051
middle aged (2401) 2401
adult (2134) 2134
antibiotics, antineoplastic - administration & dosage (2072) 2072
aged (1926) 1926
antibiotics, antineoplastic - therapeutic use (1896) 1896
oncology (1835) 1835
animals (1648) 1648
chemotherapy (1506) 1506
cancer (1382) 1382
doxorubicin - adverse effects (1191) 1191
doxorubicin (1175) 1175
treatment outcome (1046) 1046
doxorubicin - administration & dosage (949) 949
anthracyclines (913) 913
pharmacology & pharmacy (860) 860
adolescent (755) 755
mice (746) 746
neoplasms - drug therapy (729) 729
antibiotics, antineoplastic - pharmacology (723) 723
breast neoplasms - drug therapy (710) 710
antibiotics (704) 704
antineoplastic combined chemotherapy protocols - therapeutic use (702) 702
therapy (658) 658
antineoplastic combined chemotherapy protocols - adverse effects (623) 623
antineoplastic agents - adverse effects (617) 617
child (610) 610
doxorubicin - therapeutic use (555) 555
cardiotoxicity (529) 529
rats (523) 523
abridged index medicus (521) 521
risk factors (495) 495
care and treatment (493) 493
dose-response relationship, drug (481) 481
aged, 80 and over (479) 479
retrospective studies (474) 474
time factors (460) 460
toxicity (454) 454
analysis (452) 452
medicine & public health (421) 421
prospective studies (421) 421
follow-up studies (396) 396
hematology (395) 395
drug administration schedule (394) 394
bleomycin - adverse effects (389) 389
apoptosis (387) 387
child, preschool (376) 376
research (375) 375
health aspects (374) 374
drug therapy (367) 367
doxorubicin - pharmacology (361) 361
cell line, tumor (359) 359
antibiotics, antineoplastic - pharmacokinetics (358) 358
heart - drug effects (357) 357
drugs (349) 349
antineoplastic agents - therapeutic use (347) 347
heart diseases - chemically induced (346) 346
adriamycin (333) 333
tumors (332) 332
breast cancer (327) 327
surgery (306) 306
children (299) 299
combined modality therapy (296) 296
doxorubicin - analogs & derivatives (293) 293
mitomycin - administration & dosage (292) 292
antibiotics, antineoplastic - toxicity (291) 291
breast neoplasms - pathology (286) 286
neutropenia - chemically induced (283) 283
anthracyclines - adverse effects (278) 278
cardiac & cardiovascular systems (272) 272
apoptosis - drug effects (267) 267
mitomycin - adverse effects (267) 267
antineoplastic agents - administration & dosage (259) 259
young adult (256) 256
disease-free survival (252) 252
antineoplastic combined chemotherapy protocols - administration & dosage (248) 248
pediatrics (247) 247
pharmacokinetics (247) 247
trial (247) 247
liposomes (244) 244
prognosis (241) 241
survival analysis (241) 241
carcinoma (240) 240
epirubicin - administration & dosage (240) 240
drug delivery systems (238) 238
cardiomyopathies - chemically induced (232) 232
oxidative stress (231) 231
cells (230) 230
epirubicin - adverse effects (229) 229
epirubicin (227) 227
drug evaluation (226) 226
infant (225) 225
survival rate (225) 225
medicine, general & internal (222) 222
toxicology (222) 222
breast-cancer (220) 220
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (39) 39
UTL at Downsview - May be requested (2) 2
UofT at Scarborough - Stacks (2) 2
Chemistry (A D Allen) - Stacks (1) 1
Earth Sciences (Noranda) - Stacks (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
UofT at Mississauga - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6132) 6132
Japanese (171) 171
French (121) 121
German (96) 96
Russian (80) 80
Italian (50) 50
Chinese (36) 36
Spanish (31) 31
Polish (25) 25
Czech (14) 14
Danish (12) 12
Hungarian (12) 12
Finnish (7) 7
Dutch (6) 6
Norwegian (5) 5
Slovak (5) 5
Portuguese (4) 4
Romanian (3) 3
Serbian (2) 2
Croatian (1) 1
Korean (1) 1
Lithuanian (1) 1
Swedish (1) 1
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 05/2014, Volume 123, Issue 21, pp. 3239 - 3246
Journal Article
Annals of Oncology, ISSN 0923-7534, 12/2012, Volume 23, Issue 12, pp. 3069 - 3074
Luminal breast cancer is a highly endocrine responsive disease. However, the therapeutic benefit of chemotherapy (CT) in this population is not fully... 
Neoadjuvant | Chemotherapy | Hormonotherapy | Luminal breast cancer | SURVIVAL | luminal breast cancer | neoadjuvant | SUBTYPES | GENE-EXPRESSION PROFILES | PATHOLOGICAL RESPONSE | MARKERS | ENDOCRINE THERAPY | hormonotherapy | chemotherapy | TRIAL | PREOPERATIVE CHEMOTHERAPY | MOLECULAR PORTRAITS | ONCOLOGY | PROGNOSTIC-SIGNIFICANCE | Receptors, Estrogen - metabolism | Humans | Middle Aged | Antibiotics, Antineoplastic - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Ki-67 Antigen - metabolism | Antineoplastic Agents - therapeutic use | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Receptors, Progesterone - metabolism | Taxoids - therapeutic use | Receptor, Epidermal Growth Factor - metabolism | Antineoplastic Agents - adverse effects | Antineoplastic Agents, Hormonal - therapeutic use | Adult | Female | Taxoids - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Antineoplastic Agents, Alkylating - therapeutic use | Disease-Free Survival | Antibiotics, Antineoplastic - therapeutic use | Keratin-8 - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Keratin-18 - metabolism | Neoadjuvant Therapy - adverse effects | Epirubicin - therapeutic use | Aged | Antineoplastic Agents, Alkylating - adverse effects | Epirubicin - adverse effects | Index Medicus
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 09/2012, Volume 104, Issue 17, pp. 1293 - 1305
Journal Article
Cell, ISSN 0092-8674, 03/2017, Volume 169, Issue 1, pp. 132 - 147.e16
The accumulation of irreparable cellular damage restricts healthspan after acute stress or natural aging. Senescent cells are thought to impair tissue... 
Senescence | IL6 | apoptosis | FOXO4 | aging | chemotherapy | cell-penetrating peptide | TP53 | tissue homeostasis | LMNB1 | REPAIR SYNDROME TRICHOTHIODYSTROPHY | BIOCHEMISTRY & MOLECULAR BIOLOGY | FORKHEAD BOX O | DNA-DAMAGE | MOUSE MODEL | TRANSCRIPTION | INFLAMMATORY CYTOKINE SECRETION | PEPTIDE INHIBITOR | HUMAN FIBROBLASTS | CELLULAR SENESCENCE | CANCER | CELL BIOLOGY | Kidney - physiology | Antibiotics, Antineoplastic - pharmacology | Humans | Aging - drug effects | Antibiotics, Antineoplastic - adverse effects | Cellular Senescence - drug effects | Male | Cell-Penetrating Peptides - pharmacology | Liver - drug effects | Forkhead Transcription Factors - metabolism | Forkhead Transcription Factors - chemistry | Female | Inclusion Bodies - metabolism | Doxorubicin - administration & dosage | Cell Line | Kidney - drug effects | Cell Survival | Tumor Suppressor Protein p53 - metabolism | Inclusion Bodies - drug effects | Aging - pathology | Antibiotics, Antineoplastic - administration & dosage | Animals | Trichothiodystrophy Syndromes - drug therapy | Inclusion Bodies - pathology | Liver - physiology | Fibroblasts - cytology | Mice | Doxorubicin - adverse effects | Doxorubicin - pharmacology | Apoptosis | Medical colleges | Anthracyclines | Peptides | Radiation | Homeostasis | Tumor proteins | Molecular biology | Health aspects | Cells | Chemotherapy | Liver | Cancer | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2009, Volume 27, Issue 32, pp. 5410 - 5417
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2009, Volume 361, Issue 13, pp. 1235 - 1248
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2009, Volume 361, Issue 13, pp. 1249 - 1259
Patients with AML who were between 17 and 60 years of age were randomly assigned to receive induction therapy with the standard dose of daunorubicin or twice... 
CYTOSINE-ARABINOSIDE | MEDICINE, GENERAL & INTERNAL | ONCOLOGY-GROUP | INDUCTION CHEMOTHERAPY | ACUTE NONLYMPHOCYTIC LEUKEMIA | ACUTE MYELOGENOUS LEUKEMIA | ACUTE MYELOCYTIC-LEUKEMIA | GROUP-B | DAUNORUBICIN | REMISSION INDUCTION | UNTREATED ADULT PATIENTS | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Age Factors | Humans | Middle Aged | Antibiotics, Antineoplastic - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Leukemia, Myelomonocytic, Acute - drug therapy | Stem Cell Transplantation | Young Adult | fms-Like Tyrosine Kinase 3 - genetics | Leukemia, Myelomonocytic, Acute - therapy | Adult | Female | Remission Induction - methods | Daunorubicin - administration & dosage | Leukemia, Myelomonocytic, Acute - genetics | Histone-Lysine N-Methyltransferase | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Combined Modality Therapy | Cytarabine - administration & dosage | Daunorubicin - adverse effects | Antibiotics, Antineoplastic - administration & dosage | Myeloid-Lymphoid Leukemia Protein - genetics | Adolescent | Infusions, Intravenous | Mutation | Leukemia, Myelomonocytic, Acute - mortality | Anthracyclines | Usage | Daunorubicin | Young adults | Health aspects | Bone marrow | Chemotherapy | Consolidation | Kinases | Index Medicus | Abridged Index Medicus
Journal Article
Nature Medicine, ISSN 1078-8956, 05/2016, Volume 22, Issue 5, pp. 547 - 556
Doxorubicin is an anthracycline chemotherapy agent effective in treating a wide range of malignancies, but it causes a dose-related cardiotoxicity that can... 
MEDICINE, RESEARCH & EXPERIMENTAL | OXIDATIVE STRESS | RISK-FACTORS | BIOCHEMISTRY & MOLECULAR BIOLOGY | DEXRAZOXANE | INDUCED CARDIOMYOPATHY | MATURATION | MUSCLE GENE-EXPRESSION | CELL BIOLOGY | CHILDHOOD-CANCER | INHIBITION | ANTHRACYCLINE-INDUCED CARDIOTOXICITY | CONGESTIVE-HEART-FAILURE | Mitochondria, Heart - metabolism | Reactive Oxygen Species - metabolism | Antibiotics, Antineoplastic - pharmacology | Apoptosis - drug effects | Calcium - metabolism | Humans | Middle Aged | Transcriptome | Antibiotics, Antineoplastic - adverse effects | Mitochondria, Heart - drug effects | Membrane Potential, Mitochondrial - drug effects | Flow Cytometry | Adult | Female | Real-Time Polymerase Chain Reaction | Cardiotoxicity - genetics | DNA Damage - drug effects | Cell Survival - drug effects | Disease Susceptibility | Heart Failure - genetics | Breast Neoplasms - drug therapy | Myocytes, Cardiac - drug effects | Fluorescent Antibody Technique | Myocytes, Cardiac - metabolism | Aged | Polymorphism, Single Nucleotide | Oxidative Stress - drug effects | Induced Pluripotent Stem Cells | Doxorubicin - adverse effects | Doxorubicin - pharmacology | Heart Failure - chemically induced | Complications and side effects | Patient outcomes | Stem cells | Development and progression | Breast cancer | Transplantation | Cardiovascular diseases | Drug therapy | Doxorubicin | Methods | Heart failure | Chemotherapy | Toxicity | Index Medicus
Journal Article
JAMA, ISSN 0098-7484, 11/2016, Volume 316, Issue 18, pp. 1888 - 1896
IMPORTANCE: Standard dosing of chemotherapy based on body surface area results in marked interpatient variation in pharmacokinetics, toxic effects, and... 
MEDICINE, GENERAL & INTERNAL | FOLLOW-UP | THERAPY | EUROPEAN-ORGANIZATION | CMF | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antibiotics, Antineoplastic - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Epirubicin - administration & dosage | Austria | Sweden | Fluorouracil - administration & dosage | Antineoplastic Agents - adverse effects | Chemotherapy, Adjuvant - adverse effects | Adult | Female | Drug Administration Schedule | Neoplasm Recurrence, Local | Breast Neoplasms - drug therapy | Antibiotics, Antineoplastic - administration & dosage | Disease-Free Survival | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Chemotherapy, Adjuvant - methods | Quality of Life | Breast Neoplasms - mortality | Aged | Germany | Women | Chemotherapy | Usage | Adjuvant treatment | Clinical trials | Breast cancer | Diagnosis | Research | Comparative analysis | Health aspects | Cancer | Womens health | Risk factors | Index Medicus | Abridged Index Medicus | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article